MX2009001977A - Derivados profarmacologicos de aminoacilo y medicamentos para el tratamiento de enfermedades tromboembolicas. - Google Patents

Derivados profarmacologicos de aminoacilo y medicamentos para el tratamiento de enfermedades tromboembolicas.

Info

Publication number
MX2009001977A
MX2009001977A MX2009001977A MX2009001977A MX2009001977A MX 2009001977 A MX2009001977 A MX 2009001977A MX 2009001977 A MX2009001977 A MX 2009001977A MX 2009001977 A MX2009001977 A MX 2009001977A MX 2009001977 A MX2009001977 A MX 2009001977A
Authority
MX
Mexico
Prior art keywords
treatment
medicaments
prodrug derivatives
thromboembolic disorders
aminoacyl
Prior art date
Application number
MX2009001977A
Other languages
English (en)
Inventor
Elisabeth Perzborn
Hans-Georg Lerchen
Ursula Krenz
Karl-Heniz Schlemmer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2009001977A publication Critical patent/MX2009001977A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a derivados profarmacológicos de 5-cloro-N-({(5S)-2-oxo-3-[4-(3-oxomorfolin-4-il)fenil]-1,3-oxazol idin-5-il}metil)tiofen-2-carboxamida, a procedimientos para su preparación, su uso para el tratamiento y/o prevención de enfermedades, así como su uso para producir medicamentos para el tratamiento y/o la prevención de enfermedades, en especial de enfermedades tromboembólicas.
MX2009001977A 2006-08-24 2007-08-23 Derivados profarmacologicos de aminoacilo y medicamentos para el tratamiento de enfermedades tromboembolicas. MX2009001977A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006039589A DE102006039589A1 (de) 2006-08-24 2006-08-24 Aminoacyl-Prodrugs II
PCT/EP2007/007408 WO2008022786A1 (de) 2006-08-24 2007-08-23 Aminoacyl-prodrug derivate und arzneimittel zur behandlung von thromboembolischen erkrankungen

Publications (1)

Publication Number Publication Date
MX2009001977A true MX2009001977A (es) 2009-05-21

Family

ID=38694946

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001977A MX2009001977A (es) 2006-08-24 2007-08-23 Derivados profarmacologicos de aminoacilo y medicamentos para el tratamiento de enfermedades tromboembolicas.

Country Status (16)

Country Link
US (1) US8362015B2 (es)
EP (1) EP2084154B1 (es)
JP (1) JP5352461B2 (es)
KR (1) KR20090057266A (es)
CN (1) CN101547921B (es)
AU (1) AU2007287749B2 (es)
BR (1) BRPI0715741A2 (es)
CA (1) CA2661414C (es)
DE (1) DE102006039589A1 (es)
ES (1) ES2399069T3 (es)
HK (1) HK1137987A1 (es)
IL (1) IL197079A0 (es)
MX (1) MX2009001977A (es)
RU (1) RU2456283C9 (es)
WO (1) WO2008022786A1 (es)
ZA (1) ZA200901189B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006007146A1 (de) * 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
US7816355B1 (en) 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
EP2630143B1 (en) * 2010-10-18 2017-11-29 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
CA2883323A1 (en) * 2012-12-26 2014-07-03 Wanbury Ltd. Aldehyde derivative of substituted oxazolidinones
JP6998780B2 (ja) 2018-02-02 2022-01-18 株式会社デンソー 冷凍サイクル装置

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
PT1196414E (pt) * 1999-06-25 2003-12-31 Vertex Pharma Pro-farmacos de inibidores carbamato de impdh
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
TW591024B (en) * 2000-03-27 2004-06-11 Sankyo Lifetech Company Ltd An amide type triazole compound having antifungal activity
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
CA2452513A1 (en) 2001-07-12 2003-01-23 Pharmacia & Upjohn Company Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound
JP3630326B2 (ja) * 2002-08-22 2005-03-16 三共株式会社 水溶性トリアゾール医薬組成物
US7265140B2 (en) * 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
EP1893572B1 (en) * 2004-06-18 2016-12-14 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
WO2006017351A1 (en) * 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102006007146A1 (de) * 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
DE102006025314A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung

Also Published As

Publication number Publication date
US8362015B2 (en) 2013-01-29
AU2007287749B2 (en) 2013-09-12
ZA200901189B (en) 2010-04-28
KR20090057266A (ko) 2009-06-04
ES2399069T3 (es) 2013-03-25
CN101547921B (zh) 2015-01-07
CA2661414C (en) 2015-04-28
EP2084154A1 (de) 2009-08-05
HK1137987A1 (en) 2010-08-13
RU2009110246A (ru) 2010-09-27
RU2456283C2 (ru) 2012-07-20
DE102006039589A1 (de) 2008-03-06
BRPI0715741A2 (pt) 2013-07-16
RU2456283C9 (ru) 2013-05-10
US20100292230A1 (en) 2010-11-18
CA2661414A1 (en) 2008-02-28
JP2010501504A (ja) 2010-01-21
CN101547921A (zh) 2009-09-30
WO2008022786A1 (de) 2008-02-28
AU2007287749A1 (en) 2008-02-28
JP5352461B2 (ja) 2013-11-27
EP2084154B1 (de) 2012-11-21
IL197079A0 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
HK1130252A1 (en) Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders
MY143999A (en) Solid, modified-release pharmaceutical dosage forms which can be administered orally
MY145616A (en) Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
MX2009001977A (es) Derivados profarmacologicos de aminoacilo y medicamentos para el tratamiento de enfermedades tromboembolicas.
MY138386A (en) Process for the preparation of a solid, orally administrable pharmaceutical composition
WO2007039122A3 (de) Feste, oral applizierbare pharmazeutische darreichungsformen mit schneller wirkstofffreisetzung
HK1157759A1 (en) New co-crystal compound of rivaroxaban and malonic acid
ATE537168T1 (de) Substituierte oxazolidinone und ihre verwendung
TN2014000541A1 (en) Pharmaceutical administration forms comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
PH12015501625A1 (en) Aldehyde derivative of substitute oxazolidinones
WO2012080184A3 (de) Flüssige, oral applizierbare pharmazeutische zusammensetzungen enthaltend 5-chlor-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
UA94428C2 (en) Polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
UY28628A1 (es) Procedimiento para la preparación de una composición farmacéutica sólida administrable oralmente
CU23445A3 (es) Procedimiento de preparación
DOP2004001034A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente que comprende 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida en forma hidrofilizada
UY29305A1 (es) Formas de dosificación farmacéutica sólidas administrables por vía oral con liberación modificada
DOP2004001066A (es) Procedimiento de preparacion

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights